Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

A quantitative alcohol history should be recorded for all patients, because alcohol use contributes to many physical and mental disorders. A person-centered, nonjudgmental approach should be adopted.

Dr. Kalen N. Wright (Emergency Medicine): A 21-year-old man with sickle cell disease was evaluated in the emergency department of this hospital after loss of consciousness resulting in a fall.

Ten years ago, I was in the hospital battling Ebola. My fever rarely relented. I felt so weak that getting up was a herculean task, attempted only a few times a day. Having treated patients with ...

An urgent health care workforce crisis is looming. In the United States, a country plagued by disparate health outcomes across its geographic regions, relative physician “deserts” (i.e ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

Carpal tunnel syndrome affects 87 men and 192 women per 100,000 population worldwide. 1 Common signs include paresthesia, pain, and weakness in the median nerve distribution of the hand.

Zoledronate prevents fractures when given every 12 to 18 months, but its effects on bone health persist well beyond 5 years. New research findings on very infrequent zoledronate dosing in early ...

Beyond ensuring access to gender-affirming surgical care, U.S. carceral facilities can develop health care, housing, and security policies that recognize gender-affirming care as standard practice.

Patients with residual invasive HER2-positive early breast cancer after neoadjuvant systemic therapy have a poor prognosis. Adjuvant therapy with trastuzumab emtansine has shown improved outcomes.